skip to main content

United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009

SILVER SPRING, Md., Feb. 10 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 fourth quarter and annual financial results before market open on Tuesday, February 17, 2009.

United Therapeutics will host a half-hour teleconference on Tuesday, February 17, 2009, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 877-879-6209, with international callers dialing 719-325-4753. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112, with international callers dialing 719-457-0820, and using passcode: 6654716.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g]

SOURCE United Therapeutics Corporation

Contact: Andrew Fisher of United Therapeutics Corporation, +1-202-483-7000, [email protected]

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that...
An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlier detection and management of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD)An interim...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has...
Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with...
The pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups, as measured by absolute forced vital capacity (FVC), and fewer...
Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next yearSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS...